Molecular Tumor Board VITU (MOLIT Service GmbH)

The identification of molecular biomarkers is only useful if they are interpreted in a clinical context and on the basis of current scientific evidence.
If therapy-relevant biomarkers are detected, the findings are presented to the Molecular Tumor Board (MolIT) after consultation with the treating colleagues. There, possible treatment options are discussed in an interdisciplinary manner, taking into account all pathological and molecular pathological findings as well as the course of the disease to date. The treating physicians can participate online; upon request, we can present the case based on the current physician’s letter. The tumor board’s decision is usually available within a few days.